---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-014358"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:29:32.065854+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma secures $3.175M investment from Lind Partners via convertible note and warrant

## Summary
- Issued $3.704M secured convertible note to Lind Global Fund II, LP for net proceeds of $3.175M; initial conversion price $1.05/share.
- Also issued warrant to purchase up to 5,291,667 shares at $1.05/share; monthly payments start after 6 months, can be in cash or stock.
- Proceeds to fund Phase II trials for Vitargus (retinal surgery device) and ABV-1505 (ADHD drug).
- Note carries no interest; cash payments include 5% premium; default triggers 120% of outstanding principal.
- Placement agent Allele Capital Partners receives 6% cash fee and warrants for 6% of shares issuable.

## SEC filing metadata
- accession: 0001213900-23-014358
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/0001213900-23-014358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/ea174178-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-014358
- JSON: https://secwatch.observer/filing/0001213900-23-014358.json
- Plain text: https://secwatch.observer/filing/0001213900-23-014358.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $3,704,167 (effective 2023-02-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lind Global Fund II, LP
  - Value: $3,704,167
  - Effective: 2023-02-23
  source text: On February 23, 2023, ABVC BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Lind Global Fund II, LP (“Lind”), pursuant to which the Company would issue Lind a secured, convertible note in the principal amount of $3,704,167 (the “Offering”), for a purchase price of $3,175,000 (the “Note”), that is convertible into shares of the Company’s common stock at an initial conversion price of $1.05 per share, subject to adjustment (the “Note Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023014358/0001213900-23-014358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.